Nanoparticles targeting tumors loaded with a drug that makes cancer cells more vulnerable to the toxicity of chemotherapy may be a new approach in the treatment of endometrial cancer, which begins in the uterus, the researchers suggest.
Combining traditional chemotherapy with the relatively new cancer drug that targets tumor cells resistant to chemotherapy, the researchers packed both into small nanoparticles to create an extremely selective and lethal treatment for cancer.
Super-lethal nanoparticles reduced tumor growth and increased survival rates, one researcher said.
"For the first time, we were able to combine two different tumor detection strategies and use them to overcome the deadly type II endometrial cancer.
" We believe that this treatment could also be used to fight other cancers, "said the researcher. Principal Kareem Ebeid, a graduate student at the University of Iowa.
In mice with type II endometrial cancer, the team combined two anti-cancer drugs: paclitaxel, a type of chemotherapy that is used to treat endometrial cancer, and nintedanib, or BIBF 1120, a relatively new drug used to restrict the growth of tumor blood vessels.
However, in the study published in the journal Nature Nanotechnology, nintedanib was used to attack tumor cells with a specific mutation, known as Loss of p53 function that interrupts the normal life cycle of tumor cells and makes them more resistant to lethal effects It's about chemotherapy.
Paclitaxel chemotherapy killed the cells when they were in the process of cell division, but the tumor cells with the L mutation of the p53 function often slowed down this process, making the cancer more resistant to the chemotherapy treatment .
Nintedanib, on the other hand, attacked tumor cells with the mutation and forced them to divide, a point at which they were easily eliminated by chemotherapy.
"Basically, we're taking advantage of the Achilles heel of the tumor cells, the Loss of Function mutation, and then sweeping and killing them with chemotherapy," Ebeid said.
The new approach could also be used to treat other cancers, including the types of ovarian and lung cancers that also have the loss of p53 mutation function, he said.
rt / in / bg
(This story has not been edited by the Business Standard staff and is automatically generated from a syndicated feed)